Kintara Therapeutics Stock Current Valuation
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
Valuation analysis of Kintara Therapeutics helps investors to measure Kintara Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Kintara Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Kintara Therapeutics is based on 3 months time horizon. Increasing Kintara Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kintara Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kintara Stock. However, Kintara Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.3 | Real 5.67 | Hype 6.22 |
The real value of Kintara Stock, also known as its intrinsic value, is the underlying worth of Kintara Therapeutics Company, which is reflected in its stock price. It is based on Kintara Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kintara Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kintara Therapeutics helps investors to forecast how Kintara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kintara Therapeutics more accurately as focusing exclusively on Kintara Therapeutics' fundamentals will not take into account other important factors: Kintara Therapeutics Company Current Valuation Analysis
Kintara Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Kintara Therapeutics Current Valuation | 17.98 M |
Most of Kintara Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kintara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Kintara Therapeutics has a Current Valuation of 17.98 M. This is 99.87% lower than that of the Biotechnology sector and 99.61% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.89% higher than that of the company.
Kintara Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kintara Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics of similar companies.Kintara Therapeutics is currently under evaluation in current valuation category among its peers.
Kintara Fundamentals
| Return On Equity | -3.71 | |||
| Return On Asset | -1.04 | |||
| Current Valuation | 17.98 M | |||
| Shares Outstanding | 55.66 M | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 1.47 % | |||
| Number Of Shares Shorted | 5.43 M | |||
| Price To Book | 7.81 X | |||
| EBITDA | (8.5 M) | |||
| Net Income | (8.32 M) | |||
| Cash And Equivalents | 11.78 M | |||
| Cash Per Share | 0.15 X | |||
| Total Debt | 2.44 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 3.32 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (7.18 M) | |||
| Short Ratio | 1.14 X | |||
| Earnings Per Share | (11.20) X | |||
| Target Price | 14.0 | |||
| Beta | 0.81 | |||
| Market Capitalization | 11.99 M | |||
| Total Asset | 6.2 M | |||
| Retained Earnings | (159.88 M) | |||
| Working Capital | 188 K | |||
| Net Asset | 6.2 M |
About Kintara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kintara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |